4174 On Other Exchanges
Symbol
Exchange
4174 is not on other exchanges.

obi pharma inc (4174) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OBI PHARMA INC (4174)

Related News

No related news articles were found.

obi pharma inc (4174) Related Businessweek News

No Related Businessweek News Found

obi pharma inc (4174) Details

OBI Pharma, Inc. engages in the research and development of medicines. It offers OBI-888, an anti-globo H monoclonal antibody that could complement the active immunotherapy of cancer, principally for the patients undergoing radiation and/or chemo therapies. The company serves patients in hospitals and cancer treatment centers. It assists aesthetics clinics and medical markets through a network of distributors and dealers in Taiwan, China, Hong Kong, and the United States. The company was founded in 2002 and is based in Taipei, Taiwan. OBI Pharma, Inc. is a subsidiary of Optimer Pharmaceuticals.

Founded in 2002

obi pharma inc (4174) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

obi pharma inc (4174) Key Developments

OBI Pharma, Inc., Annual General Meeting, Jun 27, 2016

OBI Pharma, Inc., Annual General Meeting, Jun 27, 2016.

OBI Pharma, Inc.(GTSM:4174) added to FTSE All-World Index (USD)

OBI Pharma, Inc.(GTSM:4174) added to FTSE All-World Index (USD)

OBI Pharma Reports Results from OBI-822/821 Randomized Controlled Phase 2/3 Clinical Trial in Patients with Metastatic Breast Cancer

OBI Pharma, Inc. announced the topline results of the Phase 2/3 study of OBI-822/821 (formerly OPT822/OPT821), which evaluated the clinical benefit and immunogenicity of the investigational immunotherapy in patients with metastatic breast cancer. Based on the data available to date, the study (Protocol Number OPT-822-001) did not meet the primary efficacy end point of progression-free survival. However, patients who demonstrated an immune response (IgG or IgM) showed highly significant improvement in progression-free survival and the secondary endpoint of overall survival is trending towards statistical significance. OBI-822/821 was generally well tolerated with no major safety concerns. Full results will be presented at an upcoming international scientific conference. The study was a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 2/3 trial (NCT01516307) consisting of 9 injections of OBI-822 in a 41-week treatment period, a disease progression follow-up period of up to 2 years from randomization, and a survival follow-up period of up to 5 years. A total of 349 previously treated women with histologically or cytologically confirmed metastatic breast cancer were randomly assigned (2:1) to treatment with subcutaneous OBI-822 (equivalent to 30 µg Globo H)/OBI-821 (100 µg) or control, both in combination with intravenous low-dose CTX (300 mg/m2). Study participants were recruited from 45 medical centers in Taiwan, Hong Kong, the U.S., Korea and India. OBI-822 is a new, investigational anti-cancer treatment that belongs to a novel class of active immunotherapies. It is a synthetic glycoprotein comprised of a Tumor-Associated Carbohydrate Antigen (TACA), Globo H, covalent bounded to a carrier protein, Keyhole Limpet Hemocyanin. OBI-821 is a saponin-based adjuvant. Globo H is expressed in high levels on the surface of malignant tumors in many epithelial cancers, such as breast, prostate, gastric, lung, colon, pancreatic, and ovarian cancer, etc. The immunogenicity of the antigen is enhanced by conjugating Globo H to the KLH carrier protein to form OBI-822 (Globo H-KLH), and co-administered with an adjuvant, OBI-821. It is exclusively licensed to OBI from Memorial Sloan-Kettering Cancer Center (MSKCC).

 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4174 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4174.
View Industry Companies
 

Industry Analysis

4174

Industry Average

Valuation 4174 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 12.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact OBI PHARMA INC, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.